pegcetacoplan

Ask MedXY AI

Latest news

Tag

newsIntravitreal Therapypegcetacoplan

Two-Year Outcomes of Intravitreal Pegcetacoplan in Managing Geographic Atrophy: Real-World Clinical Experience

By MedXY|Sep 17, 2026

Intravitreal pegcetacoplan significantly slowed geographic atrophy progression by 41% over two years, maintaining efficacy in clinical practice for AMD patients, with stable visual acuity decline and manageable safety.

NephrologyC3 glomerulopathycomplement inhibition

Pegcetacoplan Markedly Reduces Proteinuria in C3 Glomerulopathy and Immune‑Complex MPGN: Results from the VALIANT Phase 3 Trial

By MedXY|Dec 3, 2025

In the phase 3 VALIANT trial, pegcetacoplan, a C3/C3b inhibitor, produced a large, rapid reduction in proteinuria versus placebo at 26 weeks in patients with C3 glomerulopathy or primary immune‑complex MPGN, with an acceptable short-term sa